Last updated: 20 June 2024 at 4:27pm EST

Jeffrey Farrow Net Worth




The estimated Net Worth of Jeffrey S Farrow is at least $9.42 Milion dollars as of 17 June 2024. Mr. Farrow owns over 27,881 units of Global Blood Therapeutics stock worth over $1,957,513 and over the last 8 years he sold GBT stock worth over $4,297,524. In addition, he makes $3,168,410 as Chief Financial Officer at Global Blood Therapeutics.

Mr. Farrow GBT stock SEC Form 4 insiders trading

Jeffrey has made over 15 trades of the Global Blood Therapeutics stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 27,881 units of GBT stock worth $1,909,570 on 17 June 2024.

The largest trade he's ever made was selling 31,441 units of Global Blood Therapeutics stock on 1 September 2022 worth over $2,137,988. On average, Jeffrey trades about 5,762 units every 63 days since 2017. As of 17 June 2024 he still owns at least 28,581 units of Global Blood Therapeutics stock.

You can see the complete history of Mr. Farrow stock trades at the bottom of the page.





Jeffrey Farrow biography

Jeffrey S. Farrow serves as Chief Financial Officer of the Company. Mr. Farrow previously served as chief financial officer of ZS Pharma, Inc., a biopharmaceutical company, which was acquired by AstraZeneca in December 2015. Prior to ZS Pharma, he served as the chief financial officer at Hyperion Therapeutics, Inc., a commercial pharmaceutical company, from July 2010 until May 2015 where he was part of the team responsible for the successful regulatory approval and commercial launch of RAVICTI® for the treatment of urea cycle disorders. He previously served as vice president of finance at Evotec AG, a drug discovery and development company. Prior to Evotec, Mr. Farrow served as vice president of finance and chief accounting officer at Renovis, Inc., a drug discovery and development company, which was acquired by Evotec AG. Earlier in his career, Mr. Farrow spent seven years working in the audit practice of KPMG LLP. Mr. Farrow holds a B.A. in business administration with a concentration in corporate finance from California State University at Fullerton and is a certified public accountant (inactive).

What is the salary of Jeffrey Farrow?

As the Chief Financial Officer of Global Blood Therapeutics, the total compensation of Jeffrey Farrow at Global Blood Therapeutics is $3,168,410. There are 5 executives at Global Blood Therapeutics getting paid more, with Ted Love having the highest compensation of $10,097,200.



How old is Jeffrey Farrow?

Jeffrey Farrow is 58, he's been the Chief Financial Officer of Global Blood Therapeutics since 2016. There are 14 older and 6 younger executives at Global Blood Therapeutics. The oldest executive at Global Blood Therapeutics Inc. is Willie Brown, 86, who is the Independent Director.

What's Jeffrey Farrow's mailing address?

Jeffrey's mailing address filed with the SEC is C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE, CA, 92618.

Insiders trading at Global Blood Therapeutics

Over the last 9 years, insiders at Global Blood Therapeutics have traded over $164,753,446 worth of Global Blood Therapeutics stock and bought 255,000 units worth $8,595,265 . The most active insiders traders include Advisors Llcperceptive Life..., Rock Ventures Ii, L.P.Third... a Kevin P Starr. On average, Global Blood Therapeutics executives and independent directors trade stock every 14 days with the average trade being worth of $3,133,144. The most recent stock trade was executed by Nazila Habibizad on 1 October 2022, trading 1,557 units of GBT stock currently worth $106,639.



What does Global Blood Therapeutics do?

Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company's next generation hemoglobin S polymerization inhibitor. In addition, GBT's drug discovery teams are working on new targets to develop the next wave of treatments for SCD.



What does Global Blood Therapeutics's logo look like?

Global Blood Therapeutics Inc. logo

Complete history of Mr. Farrow stock trades at Global Blood Therapeutics a Tarsus Pharmaceuticals

Datum
#
Společnost
Osoba
Trans.
Transakce
Počet akcií Cena za akcii Celková cena Počet akcií po Zdroj
17 Jun 2024 Jeffrey S Farrow
See Remarks
Využití opce 27,881 $28.84 $804,088
17 Jun 2024
28,581
27 Sep 2022 Jeffrey S Farrow
Finanční ředitel
Využití opce 23,653 $16.40 $387,909
27 Sep 2022
26,739
1 Sep 2022 Jeffrey S Farrow
Finanční ředitel
Prodej 31,441 $68.00 $2,137,988
1 Sep 2022
3,086
1 Aug 2022 Jeffrey S Farrow
Finanční ředitel
Využití opce 6,145 $32.40 $199,098
1 Aug 2022
33,567
1 Mar 2022 Jeffrey S Farrow
Finanční ředitel
Využití opce 2,763 $29.87 $82,531
1 Mar 2022
28,737
1 Feb 2022 Jeffrey S Farrow
Finanční ředitel
Využití opce 9,020 $29.33 $264,557
1 Feb 2022
30,480
1 Sep 2021 Jeffrey S Farrow
Finanční ředitel
Využití opce 2,762 $29.85 $82,446
1 Sep 2021
22,830
1 Aug 2021 Jeffrey S Farrow
Finanční ředitel
Využití opce 9,020 $27.33 $246,517
1 Aug 2021
24,422
1 Feb 2021 Jeffrey S Farrow
Finanční ředitel
Využití opce 12,083 $49.49 $597,988
1 Feb 2021
21,267
1 Aug 2020 Jeffrey S Farrow
Finanční ředitel
Využití opce 12,082 $67.48 $815,293
1 Aug 2020
15,130
13 Jul 2020 Jeffrey S Farrow
Finanční ředitel
Prodej 15,208 $75.00 $1,140,600
13 Jul 2020
3,048
9 Jun 2020 Jeffrey S Farrow
Finanční ředitel
Prodej 15,208 $67.00 $1,018,936
9 Jun 2020
18,256
1 Feb 2020 Jeffrey S Farrow
Finanční ředitel
Využití opce 9,063 $65.26 $591,451
1 Feb 2020
37,862
13 Dec 2019 Jeffrey S Farrow
Finanční ředitel
Využití opce 5,000 $76.88 $384,400
13 Dec 2019
31,278
27 Nov 2018 Jeffrey S Farrow
Finanční ředitel
Využití opce 3,048 $16.40 $49,987
27 Nov 2018
15,555


Global Blood Therapeutics executives and stock owners

Global Blood Therapeutics executives and other stock owners filed with the SEC include: